Description: Review a recently completed research project for a multi-stakeholder data consortium on social determinants of health (SDOH). In this project, claims, external SDOH data, geospatial analysis, and machine learning models were used to examine several questions: How to identify SDOH vulnerabilities? How sensitive are the findings with respect to provider coding pattern variations? How much variability in cost can be explained by SDOH vs. morbidity? What are the key risk drivers revealed by machine learning models? The session will review the methodology and main findings from this project.

Description: Focus on how innovative health care organizations develop their value proposition for their intended buyers. Presenters will share information about their specific solution and the methods used to derive credible savings estimates, ROI, and performance guarantees. Learn about data utilized, the methods deployed, advantages, disadvantages, and buyers' reaction. This session is expected to be technical, highly informative, and interactive with audience members.

Description: In this session, you will learn about key cost drivers in pharmacy trends, including but not limited to: New high-cost drugs, including gene therapies, that treat rare and/or expensive conditions such as spinal muscular atrophy (SMA), inherited retinal disease, hemophilia A and B, Duchenne muscular dystrophy (DMD), sickle cell anemia and cerebral adrenoleukodystrophy (CALD) Other cost drivers in the prescription drug category, including the emergence of GLP-1s, digital therapeutics, targeted immunomodulators, accelerated approval drugs and expanded indications The implications of the end of the COVID-19 Public Health Emergency (PHE) on the costs of COVID-19 vaccines, testing and treatment claims Downward influences on pharmacy costs, such as the availability of new generic drugs and biosimilars Emerging trends in pharmacy benefits manager (PBM) contracting, the initial portion of this discussion will be led by a pharmacist and former state pharmacy director.

Description: After three decades of relatively stable overall inflation trends, the United States has seen significant increases over the last twelve months. What could this mean for inflation in the medical sector? Explore past patterns between the two phenomena, and what drivers stakeholders can monitor to be best aware of what could be coming.

Description: The session will highlight trends in recent industry mortality and lapse studies that have been conducted, including areas where individual companies typically have limited data. The sources of data feature SOA studies as well as other industry studies conducted by consultants and/or reinsurers. Gain an understanding of current drivers of mortality and lapse experience for life insurance evidenced in industry studies, and an understanding of available data to supplement experience in areas where you may have limited internal experience.

Description: In light of recent regulatory developments and international best practices, the Bermuda Monetary Authority has introduced proposed enhancements to the Bermuda regulatory framework for long-term commercial insurers. During this panel discussion, discuss the potential impacts of these proposed regulatory changes for existing commercial insurers and new entrants to the Bermuda life reinsurance market.

Description: Most, if not all of us, have experienced a time when we were involved in a conversation that made us uncomfortable. After a short presentation to provide things to consider prior or during a difficult conversation, attendees will work at their tables to discuss a variety of topics. After each topic has been discussed, someone at each table will be given the opportunity to share something insightful with the group.

Description: Join a discussion on the tax implications for direct writers ceding annuity blocks for both onshore and offshore reinsurance arrangements. Get an introduction to the tax consequences of the risk transfer of annuity features and guarantees to reinsurers to reinsurers that are U.S.-based and not U.S. domiciled.

Description: Participate in a discussion with panelists from various functional areas andcompanies about the trend of increasing mutual attractions between private equity and insurance companies, the underlying strategic drivers from both sides, as well as the impact to both individual insurance companies and insurance industry as a whole. Take part in a conversation about the implications of insurers' obligations/changes to risk profiles and exposures when engaging offshore domicile of affiliated and unaffiliated reinsurers involved in the private equity-owned insurance business.

Description: Gain a high-level understanding on how long-duration targeted improvement (LDTI) impacts insurance products and earnings. Explore highlights on secondary impacts to companies due to additional complexity of LDTI, such as a need for a source of earnings analysis. Then dive into the details and hear an explanation on how earnings emergence differs for each type of life and annuity product impacted by LDTI. Finally, discuss the impact -to-earnings volatility under LDTI for each product type. Close the session by connecting how the investor story changes with all the impacts discussed during the session.You should walk away with a good understanding of LDTI earnings emergence, which is a topic that has very limited thought leadership available today.